The PHARMAC Rare Disorders Advisory Committee has RECOMMENDED the funding of 2nd generation enzyme replacement therapy (ERT) Nexviazyme (avalglucosidase alfa) for treating Pompe Disease. This recommendation is for both infantile onset Pompe (IOPD) and Late onset Pompe (LOPD). To read the full press release, please click on the link below.